Refine by
Cardiovascular Function Articles & Analysis
5 news found
Responding to the surging global demand for specialized bioactive ingredients, the chemical and material supplier Alfa Chemistry has significantly expanded its catalogue of high-purity hydrolyzed protein peptides. The company now prominently features a diverse range, including sought-after marine-sourced peptides like Fish Collagen Peptide, Marine Fish Oligopeptide, Oyster Peptide, and Sea ...
As an active player in chemical manufacturing and research, Alfa Chemistry exhibits its deep marine chemistry expertise through the addition of marine extracts, oils, and natural products to its portfolio. The company's strategic initiative demonstrates its resolution to utilize marine resources for multiple industries including pharmaceuticals and cosmetics. Marine Natural Products The ...
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
MINNEAPOLIS, Nov. 2, 2020 - CVRx®, developer of the world's first FDA-approved neuromodulation device to treat chronic heart failure (HF), announces that its BAROSTIM NEO™ implantable device has received the Centers for Medicare & Medicaid Services (CMS) inpatient New Technology Add-On Payment (NTAP). Additionally, CMS proposed national coverage determination (NCD) for Breakthrough ...
ByCVRx
MINNEAPOLIS, July 7, 2020 /PRNewswire/ — CVRx, Inc., a private medical device company with a novel technology that treats patients suffering from chronic heart failure (“HF”) and resistant hypertension, announced today that it raised $50 million to close its latest round of equity financing. Proceeds from the financing will be used to support commercialization of the BAROSTIM ...
ByCVRx